LCNB (LCNB) has put up a clean Q2 2026 scorecard, with total revenue of about US$24.9 million and basic EPS of roughly US$0.53, backed by quarterly net income of US$7.5 million. Over the last few quarters, revenue has ranged from about US$21.2 million to US$24.9 million, while quarterly EPS has moved between roughly US$0.31 and US$0.53. This gives investors a clearer view of how earnings are tracking through the cycle. With a trailing net profit margin of 26.5% and a net interest margin of 3.99% in the latest quarter, the story this season is about how sustainably LCNB can defend its profitability profile.
See our full analysis for LCNB.With the latest numbers on the table, the next step is to see how this earnings profile lines up with the most common narratives around LCNB's growth, risks, and income appeal.
Curious how numbers become stories that shape markets? Explore Community Narratives
For a fuller breakdown of how these earnings, margin, and valuation pieces fit into the broader story for LCNB, it helps to see how different investors are interpreting the same set of numbers through structured narratives, including where they agree and where they push back on each other through the latest community discussion threads.📊 Read the what the Community is saying about LCNB.
Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on LCNB's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.
If the mix of positives and concerns around LCNB still feels finely balanced, take a moment to review the data yourself and decide how it fits your portfolio. Then finish by checking the 3 key rewards.
LCNB's outlook combines an expected 9.8% annual revenue decline, modest 4.2% earnings growth, and rising non performing loans, which limits comfort around long term momentum.
If those trends leave you wanting stronger growth support, you may wish to broaden your search to companies screened for healthier profiles using the 46 high quality undervalued stocks and see what opportunities stand out today.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com